Clinical Trial Update: Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) [Phase 1]

View source ↗

Summary

Phase 1 study of Ulevostinag (MK-1454) alone or in combination with pembrolizumab (MK-3475) in participants with advanced/metastatic solid tumors or lymphomas h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Ulevostinag (MK-1454)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Solid Tumors, Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2024-02-26